PURPOSE: We aimed to develop a clinical decision support tool for clinicians counseling patients with localized prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The tool would provide estimates of patient life expectancy from age, comorbidities, and tumor characteristics. We reviewed the literature to find suitable prediction models.
MATERIALS AND METHODS: We searched the literature for prediction models for life expectancy. Models were evaluated in terms of whether they provided an estimate of risk, incorporated comorbidities, were clinically feasible and gave plausible estimates. Clinical feasibility was defined in terms of whether the model provided coefficients, could be used in the initial consultation for men across a wide range of ages without an undue burden of data gathering.
RESULTS: Models in the literature were characterized by the use of life years rather than a risk of death, questionable approaches to comorbidities, implausible estimates, questionable recommendations, and poor clinical feasibility. We found tools based on applying an unvalidated approach to assessing comorbidities to a clearly erroneous life expectancy table, or required a treatment decision be made before life expectancy could be calculated or gave highly implausible estimates, such as a substantial risk of prostate cancer specific mortality even for a highly comorbid 80 year old with Gleason 6 disease.
CONCLUSIONS: We found gross deficiencies in current tools that predict risk of death from other causes. No existing model was suitable for implementation in our clinical decision support system.
Kent M, Vickers AJ. Are you the author?
Memorial Sloan-Kettering Cancer Center, Department of Epidemiology and Biostatistics, Health Outcomes Research Group.
Reference: J Urol. 2014 Nov 15. pii: S0022-5347(14)04929-5.